Brought to you by 
Series C brings $37mm to Concert Pharmaceuticals
02 May 2008
Executive Summary
Concert Pharmaceuticals (deuterium-based drug discovery technology) raised $37mm through its Series C round. An undisclosed public institutional investor led, and was joined by new buyers Adage Capital Management, SR One, Mediphase Venture Partners, and Westfield Capital Management. Existing backers Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners, Flagship Ventures, Greylock Partners, New Leaf Venture Partners, and QVT Fund also participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings $37mm to Concert Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice